ArticleJAAD case reports2023
Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases.
Article in JAAD case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Hypertrophic lupus erythematosus hypertrophic lichen planus overlap responding to acitretin and anifrolumab.JAAD case reports · 2025Article
- Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus.JAAD case reports · 2025Article
- Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report.SAGE open medical case reports · 2025Article
- Treatment of recalcitrant discoid lupus erythematosus with roflumilast 0.3% cream following suboptimal response to anifrolumab and improvement of hypopigmentation.JAAD case reports · 2024Article
- Anifrolumab for the treatment of refractory chilblain lupus erythematosus.JAAD case reports · 2024Article
- Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab.Mediterranean journal of rheumatology · 2024Article
- Rapid response of refractory subacute cutaneous lupus after single dose anifrolumab.JAAD case reports · 2024Article
- Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.